Development of an mRNA-lipid nanoparticle vaccine against Lyme disease
Title | Development of an mRNA-lipid nanoparticle vaccine against Lyme disease |
Publication Type | Journal Article |
Year of Publication | 2023 |
Journal | Mol Ther |
Volume | 31 |
Issue | 9 |
Start Page | 2702 |
Date Published | 09/2023 |
Authors | Pine M, Arora G, Hart TM, Bettini E, Gaudette BT, Muramatsu H, Tombacz I, Kambayashi T, Tam YK, Brisson D, Allman D, Locci M, Weissman D, Fikrig E, Pardi N |
Keywords | antibody, antigen, bacteria, borrelia burgdorferi, lipid nanoparticle, Lyme disease, mRNA, nucleoside-modification, OspA, spirochete, vaccine |
Abstract | Lyme disease is the most common vector-borne infectious disease in the United States, in part because a vaccine against it is not currently available for humans. We propose utilizing the lipid nanoparticle-encapsulated nucleoside-modified mRNA (mRNA-LNP) platform to generate a Lyme disease vaccine like the successful clinical vaccines against SARS-CoV-2. Of the antigens expressed by Borrelia burgdorferi, the causative agent of Lyme disease, outer surface protein A (OspA) is the most promising candidate for vaccine development. We have designed and synthesized an OspA-encoding mRNA-LNP vaccine and compared its immunogenicity and protective efficacy to an alum-adjuvanted OspA protein subunit vaccine. OspA mRNA-LNP induced superior humoral and cell-mediated immune responses in mice after a single immunization. These potent immune responses resulted in protection against bacterial infection. Our study demonstrates that highly efficient mRNA vaccines can be developed against bacterial targets. |
URL | https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(23)00428-8?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1525001623004288%3Fshowall%3Dtrue |